Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4)
- Target
- CTLA-4
- Molecular classification
- Immunoglobulin superfamily, Receptor, CD28 subfamily
01
Overview
Cytotoxic T-lymphocyte protein 4 (CTLA-4), also known as CD152, is a cell surface receptor that plays a critical role in regulating immune responses. It is primarily expressed on activated T cells and regulatory T cells (Tregs). CTLA-4 functions as an inhibitory immune checkpoint, acting to dampen or "brake" the activation of the immune system to maintain self-tolerance and prevent autoimmunity. CTLA-4 binds with high affinity to B7 family ligands (CD80/B7-1 and CD86/B7-2) on antigen-presenting cells, outcompeting CD28 for binding and delivering inhibitory signals.
- Other names
- CD152
02
Mechanism of action
Blocking CTLA-4 to enhance anti-tumor immunity
03
Biological functions
Immune responseRegulation of immune homeostasisT-cell regulationInhibitory immune checkpoint
04
Disease associations
AutoimmunityCancer
05
Safety considerations
Immune-related adverse events (irAEs) due to unleashing of the immune system against healthy tissues
06
Interacting drugs
Ipilimumab
1 more in the full profile.
Beyond the preview
Go deeper on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4).